Hepatol Int. 2007 Mar;1(1):267-73. doi: 10.1007/s12072-007-5001-0.
Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study.
Hepatology international
Yi-Cheng Chen, Chia-Ming Chu, Chau-Ting Yeh, Yun-Fan Liaw
Affiliations
Affiliations
- Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University, 199, Tung Hwa North Road, Taipei, 105, Taiwan, [email protected].
PMID: 19669348
PMCID: PMC2720722 DOI: 10.1007/s12072-007-5001-0
Abstract
PURPOSE: To elucidate the long-term natural course following the onset of cirrhosis in patients with chronic hepatitis B.
METHODS: Ninety-three patients with chronic hepatitis B who had developed cirrhosis during regular follow-up were included in this long-term follow-up study. At the time of cirrhosis detection, 30% of the patients were seropositive for hepatitis B e antigen (HBeAg) and 73% had a HBV-DNA level >10(4) copies/ml. Follow-up studies included liver biochemistry, viral markers, alpha-fetoprotein and ultrasonography every 3-6 months.
RESULTS: During a mean follow-up period of 102 +/- 60 (12-246; median 97) months, 32 patients (34.4%) experienced 55 episodes of hepatitis flare (7.0%/year), 15 (53.6%) of 28 HBeAg-positive patients seroconverted to anti-HBe (6.3%/yr) and 12 (12.9%) lost HBsAg (1.5%/year). Overall disease progression was observed in 25 (26.9%, 3.2%/year) patients: 12 (12.9%, 1.5%/year) hepatic decompensation, 21 (22.6%, 2.7%/year) hepatocellular carcinoma and 11 (11.8%, 1.4%/year) died. Multivariate analysis showed that age at onset of cirrhosis (P = 0.015) and persistent HBeAg seropositivity (P = 0.019) were the independent factors for overall disease progression.
CONCLUSIONS: These results suggest that patients with older age at onset of cirrhosis and persistent HBeAg seropositivity following the onset of cirrhosis were independent factors for the disease progression in the first 10-year after the development of cirrhosis in patients with chronic hepatitis B.
References
- Gut. 2004 May;53(5):744-9 - PubMed
- J Hepatol. 1990 Jan;10(1):29-34 - PubMed
- Gastroenterology. 1986 Feb;90(2):263-7 - PubMed
- J Viral Hepat. 2004 Mar;11(2):97-107 - PubMed
- Hepatology. 1988 May-Jun;8(3):493-6 - PubMed
- Hepatology. 1991 Apr;13(4):627-31 - PubMed
- J Gastroenterol Hepatol. 2003 Mar;18(3):246-52 - PubMed
- Am J Gastroenterol. 2002 Nov;97(11):2886-95 - PubMed
- Semin Liver Dis. 2006 May;26(2):142-52 - PubMed
- Hepatology. 1995 Jan;21(1):77-82 - PubMed
- Intervirology. 2003;46(2):96-104 - PubMed
- Hepatology. 1987 Jan-Feb;7(1):20-3 - PubMed
- Liver Int. 2005 Apr;25(2):220-5 - PubMed
- Gastroenterology. 1992 Nov;103(5):1630-5 - PubMed
- Liver. 1989 Aug;9(4):235-41 - PubMed
- Antivir Ther. 2006;11(6):669-79 - PubMed
- Gastroenterology. 2002 Oct;123(4):1084-9 - PubMed
- J Hepatol. 2007 Jan;46(1):45-52 - PubMed
- J Clin Ultrasound. 1993 Jun;21(5):303-8 - PubMed
- Am J Epidemiol. 1997 Jun 1;145(11):1039-47 - PubMed
- Liver. 1990 Jun;10(3):177-84 - PubMed
- J Clin Gastroenterol. 2002 May-Jun;34(5):569-72 - PubMed
Publication Types